Replies to post #133585 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607470/

Informative article on yet an topic the board has already previously debated Ad nauseam.

Do read, but I think patent protection and exclusivity is fine for A2-73 based upon the granted A2-73PLUS patent.

“Conclusion
FDC approvals significantly increased over the last twenty years. Pharmaceutical companies market FDC drugs shortly before the generic versions of the single ingredients enter the market extending the patent and exclusivity life of drugs included in the combination.”

“In the US, if a FDC is novel, non-obvious, and useful, it can be patented and the exclusion of competitors from the market can be enforced (Fig 2). In this case, the sponsor company is able to add patent and exclusivity time to the combination of individual products included in the FDC, for which patents and exclusivities may be expired or close to expire. “